Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Understanding the Myelodysplastic Syndromes.

Kouides1, Bennett

  • 1University of Rochester School of Medicine and Dentistry, Department of Medicine, Rochester General Hospital, Rochester, New York, 14621, USA. pkouides@rghnet.edu

The Oncologist
|January 1, 1997
PubMed
Summary

Myelodysplastic syndromes (MDS) are clonal bone marrow disorders characterized by impaired differentiation and increased apoptosis. Risk stratification using the International Prognostic Scoring System guides treatment for MDS patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

On the Molecular Organ of the Tissues.

Medical examiner (Philadelphia, Pa.)·2023
Same author

Laryngeal and Paryngeal Diseases, Mistaken for Phthisis.

Iowa medical journal·2023
Same author

Injuries to the colon.

Proceedings of the Congress of C.M.F. Army Surgeons. Congress of C.M.F. Army Surgeons (1945 : Rome, Italy)·2010
Same author

Autopsy report; sudden death in a 54 year old farmer suffering from draining sinuses on the neck of 15 months duration.

The Quarterly bulletin of the Indiana University Medical Center·2010
Same author

Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline.

Neurology·2007
Same author

Erratum to 'Health care in Hong Kong and mainland China: one country, two systems?'.

Health policy (Amsterdam, Netherlands)·2000

Area of Science:

  • Hematology
  • Oncology
  • Cell Biology

Background:

  • Myelodysplastic syndromes (MDS) present diagnostic and management challenges.
  • MDS is a clonal bone marrow disorder with impaired cell differentiation.
  • Extensive apoptosis contributes to the characteristic peripheral cytopenias despite marrow hyperplasia.

Purpose of the Study:

  • To review the diagnostic and management strategies for myelodysplastic syndromes.
  • To highlight the role of apoptosis and clonal nature in MDS pathogenesis.
  • To discuss the utility of the International Prognostic Scoring System (IPSS) for risk stratification and treatment guidance.

Main Methods:

  • Review of recent studies and clinical observations regarding MDS.
  • Application of the International Prognostic Scoring System (IPSS) incorporating marrow blasts, cytopenias, and chromosomal abnormalities.

Related Experiment Videos

  • Analysis of prognostic subgroups and corresponding survival data.

    • Main Results:

    • MDS diagnosis requires exclusion of other disorders causing dysplasia and cytopenias.
    • Neutropenia and neutrophil dysfunction increase infection risk, the leading cause of death in MDS.
    • The IPSS categorizes patients into four risk groups (low to high) with distinct median survival rates (0.4 to 5.7 years).

    Conclusions:

    • MDS management should be tailored to patient-specific prognostic subgroups.
    • Low-risk MDS may benefit from hematopoietic growth factors, while high-risk patients are candidates for AML-induction therapy or novel agents.
    • Further understanding of MDS molecular biology is crucial for improving patient care.